News
SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not thrombosis among patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback